Antibody Therapies
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
200
NCT04064359
Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors
Phase: Phase 1
Role: Lead Sponsor
Start: Jul 25, 2019
Completion: Dec 31, 2027
Loading map...